Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy
ObjectiveThe Charlson Comorbidity Index (CCI) is a widely utilized assessment tool for evaluating the mortality rate among patients with chronic diseases and tumors. Currently, there is a dearth of research investigating the correlation between CCI and survival rates in advanced pancreatic cancer pa...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1487318/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542892239880192 |
|---|---|
| author | Nan Zhang Nan Zhang Shiyun Chen Yue Shi Zhikuan Wang Ru Jia Guanghai Dai Guanghai Dai |
| author_facet | Nan Zhang Nan Zhang Shiyun Chen Yue Shi Zhikuan Wang Ru Jia Guanghai Dai Guanghai Dai |
| author_sort | Nan Zhang |
| collection | DOAJ |
| description | ObjectiveThe Charlson Comorbidity Index (CCI) is a widely utilized assessment tool for evaluating the mortality rate among patients with chronic diseases and tumors. Currently, there is a dearth of research investigating the correlation between CCI and survival rates in advanced pancreatic cancer patients received immunotherapy. Therefore, this study aims to elucidate the association between CCI and survival rates in real-world settings for pancreatic cancer patients received immunotherapy.MethodsA total of 104 patients with advanced pancreatic cancer who received immunotherapy at the General Hospital of the People’s Liberation Army between September 2015 and September 2020 were included in this study. The patients were categorized into two groups based on their Charlson Comorbidity Index (CCI) scores: low CCI group (CCI <7) and high CCI group (CCI ≥7). The statistical analysis focused on examining the correlation between CCI score and survival outcome.ResultsThe high CCI group exhibited significantly lower overall survival (OS) and progression-free survival (PFS) compared to the low CCI group (p<0.05). The median OS for the high CCI and low CCI groups were 7.82 and 44.17 months, respectively, while the median PFS were 2.40 and 6.40 months, respectively. Multivariate analysis revealed that high CCI was independently risk factor for both OS (HR=2.801, 95%CI: 1.433-5.472, p=0.003) and PFS (HR=2.546, 95%CI: 1.389-4.668, p=0.003).ConclusionThe CCI score serves as a significant independent predictive indicator for advanced pancreatic cancer patients received immunotherapy. |
| format | Article |
| id | doaj-art-4ee39c15355e47c28568fa8b30eba40b |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-4ee39c15355e47c28568fa8b30eba40b2025-02-03T12:19:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.14873181487318Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapyNan Zhang0Nan Zhang1Shiyun Chen2Yue Shi3Zhikuan Wang4Ru Jia5Guanghai Dai6Guanghai Dai7Medical School of Chinese PLA, Beijing, ChinaDepartment of Medical Oncology, the First Medical Center, Chinese PLA General Hospital, Beijing, ChinaDepartment of Medical Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, ChinaDepartment of Medical Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, ChinaDepartment of Medical Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, ChinaDepartment of Medical Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, ChinaDepartment of Medical Oncology, the First Medical Center, Chinese PLA General Hospital, Beijing, ChinaDepartment of Medical Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, ChinaObjectiveThe Charlson Comorbidity Index (CCI) is a widely utilized assessment tool for evaluating the mortality rate among patients with chronic diseases and tumors. Currently, there is a dearth of research investigating the correlation between CCI and survival rates in advanced pancreatic cancer patients received immunotherapy. Therefore, this study aims to elucidate the association between CCI and survival rates in real-world settings for pancreatic cancer patients received immunotherapy.MethodsA total of 104 patients with advanced pancreatic cancer who received immunotherapy at the General Hospital of the People’s Liberation Army between September 2015 and September 2020 were included in this study. The patients were categorized into two groups based on their Charlson Comorbidity Index (CCI) scores: low CCI group (CCI <7) and high CCI group (CCI ≥7). The statistical analysis focused on examining the correlation between CCI score and survival outcome.ResultsThe high CCI group exhibited significantly lower overall survival (OS) and progression-free survival (PFS) compared to the low CCI group (p<0.05). The median OS for the high CCI and low CCI groups were 7.82 and 44.17 months, respectively, while the median PFS were 2.40 and 6.40 months, respectively. Multivariate analysis revealed that high CCI was independently risk factor for both OS (HR=2.801, 95%CI: 1.433-5.472, p=0.003) and PFS (HR=2.546, 95%CI: 1.389-4.668, p=0.003).ConclusionThe CCI score serves as a significant independent predictive indicator for advanced pancreatic cancer patients received immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1487318/fullpancreatic cancerimmune checkpoint inhibitorsCharlson syndrome indexsurvivalimmunotherapy combined therapy |
| spellingShingle | Nan Zhang Nan Zhang Shiyun Chen Yue Shi Zhikuan Wang Ru Jia Guanghai Dai Guanghai Dai Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy Frontiers in Immunology pancreatic cancer immune checkpoint inhibitors Charlson syndrome index survival immunotherapy combined therapy |
| title | Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy |
| title_full | Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy |
| title_fullStr | Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy |
| title_full_unstemmed | Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy |
| title_short | Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy |
| title_sort | charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy |
| topic | pancreatic cancer immune checkpoint inhibitors Charlson syndrome index survival immunotherapy combined therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1487318/full |
| work_keys_str_mv | AT nanzhang charlsonsyndromeindexpredictedsurvivalinpancreaticcancerpatientsreceivedimmunotherapy AT nanzhang charlsonsyndromeindexpredictedsurvivalinpancreaticcancerpatientsreceivedimmunotherapy AT shiyunchen charlsonsyndromeindexpredictedsurvivalinpancreaticcancerpatientsreceivedimmunotherapy AT yueshi charlsonsyndromeindexpredictedsurvivalinpancreaticcancerpatientsreceivedimmunotherapy AT zhikuanwang charlsonsyndromeindexpredictedsurvivalinpancreaticcancerpatientsreceivedimmunotherapy AT rujia charlsonsyndromeindexpredictedsurvivalinpancreaticcancerpatientsreceivedimmunotherapy AT guanghaidai charlsonsyndromeindexpredictedsurvivalinpancreaticcancerpatientsreceivedimmunotherapy AT guanghaidai charlsonsyndromeindexpredictedsurvivalinpancreaticcancerpatientsreceivedimmunotherapy |